Clearmind Medicine (NASDAQ: CMND) announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase 1/2a clinical trial evaluating CMND-100 in patients with moderate-to-severe alcohol use disorder (AUD).
Part B marks Clearmind’s first clinical evaluation of CMND 100 in patients diagnosed with AUD, following the successful completion of Part A in healthy volunteers. Part B consists of two sequential single-dose ascending cohorts (80 mg and 160 mg), each consisting of six patients, designed to assess safety, tolerability, pharmacokinetics, and early signals of clinical efficacy, including potential reductions in alcohol craving.
In a statement, Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “Completing recruitment for the first portion of Part B marks a significant advancement for our CMND 100 clinical program, as we transition from healthy volunteers to the very patient population we aim to impact. Building on the safety and tolerability data observed in Part A and the continued support of our clinical partners, we are now positioned to generate the first dedicated clinical dataset evaluating CMND-100 in individuals with AUD—a major milestone toward validating its therapeutic potential in a large and underserved market.”
The trial is being conducted at leading clinical sites in the U.S. and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
